Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT06998446

Conditions

Eczema

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above.

The study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether skin sodium concentration is linked to atopic dermatitis and immune profiles over time.

Participants will be asked to complete questionnaires, provide bio samples, and undergo non-contrast sodium MRI at 2-3 time points over 3-24 months.

Conditions

Eczema

Atopic Dermatitis

Study ID

NCT06998446

Start date

May 12, 2025

Status verified date

Jul, 2026

Completion date

Aug 30, 2028

Anticipated

Primary completion date

Aug 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Ages 50 years and above
  • Willing to undergo non-contrast MRI (e.g., no contraindications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips or pregnancy).

Exclusion Criteria:

  • History of autoimmune disease.
  • Cardiac events in the last six months.
  • Impaired function of the liver or kidneys (glomerular filtration rate <60ml/min).
  • Current use of medications that influence sodium excretion (e.g. thiazide diuretics, SGLT2 inhibitors and spironolactone), and/or chemotherapy or antibiotic treatment.
  • Currently receiving phototherapy or taking systemic medications for atopic dermatitis including cyclosporine, methotrexate, or other broad immunosuppressive medications.

(Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the criteria for severe disease.)

Study Design

Enrollment

90 participants

Anticipated

Interventions and Outcome Measures

Arms

No History of AD

Healthy controls

Mild AD

Eczema Area Severity Index (EASI): scores <7 will be considered mild AD

Severe AD

Eczema Area Severity Index (EASI): scores >21 will be considered severe

Primary outcome measure

  • Skin sodium concentration [ Time Frame: 2 years ]
  • Atopc dermatitis serverity [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Jie Zhu, MD

415-502-0433Jie.Zhu2@ucsf.edu

Katrina Abuabara, MD

415-514-9769katrina.abuabara@ucsf.edu

Locations

San Francisco VA Medical Center

Recruiting

San Francisco, California, United States, 94115

Contacts

Frank Asare-Bediako, BS

520-304-8529frank.asarebediako@ucsf.edu

Principal Investigator:

Theodora Mauro, MD

UCSF Mt Zion Campus

Recruiting

San Francisco, California, United States, 94511

Contacts

Jie Zhu, MD

415-502-0433Jie.Zhu2@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Jul 14, 2026

Last verified

Jul, 2026

Keywords

  • Sodium
  • Salt

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-07-14.